One of the most important markets in Latin America already has MHYOSPHERE® PCV ID, the first needle-free intradermal vaccine against Mycoplasma hyopneumoniae and PCV2, all in one: Mexico.

Considering the current situation we live in with mobility restrictions, HIPRA organized a double launch of MHYOSPHERE® PCV ID:

A first face-to-face event with an exclusive group of clients who met in Valle de Bravo (State of Mexico), following all the anti-COVID security measures, to whom the vaccine and its services were presented through an interactive life event with HIPRA Headquarters, and with the collaboration of speakers from Brazil, the United States and Spain.

And a week later, a second online event was held where the participants attended the presentation of the vaccine and were able to actively participate live in a round table with the speakers, a whole immersive and exclusive experience. 

The launch of MHYOSPHERE® PCV ID in Mexico represents a great step forward in the future of HIPRA in the Mexican market and the Latin American environment.

It is a completely innovative vaccine that will provide the producer with a whole series of benefits non-existent until now, in terms of Mycoplasma and Circovirus vaccination. This product is released on the market as a clear example of HIPRA’s commitments: “Without innovation, there is no project”.